Regeneron Pharmaceuticals
New York
Pharmaceuticals Biotechnology and Life Sciences
Corporate Bias Rating
Collapse Summary
Risk Level:
High Risk
Summary:
Regeneron Pharmaceuticals is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Regeneron embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportShareholder Proposals
Collapse Summary
Date | ESG Category | Proponent | Summary of Resolution | Mgmt Rec | Total Vote % in Favor |
|---|---|---|---|---|---|
| 6/9/23 | Social | Boston Common Asset Management | Report on a process by which access to medicine is considered in matters related to protecting intellectual property | Against | 9.38% |